A breakthrough targeted therapy, mirvetuximab soravtansine, is offering new hope to women with hard-to-treat ovarian cancer. Studies show it extends survival, slows disease progression, shrinks ...

Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, ...

An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing surveillance, emphasizing the importance of reporting unexpected adverse events to ...

New research by Wistar Institute scientists shows how targeting a cleft in the retinoblastoma protein can kill tumor-protecting macrophages in ovarian cancer. The discovery provides a novel ...

Women taking the drug tell the BBC it has given them their lives back.

Michigan State University researchers have identified how ovarian cancer cells become resistant to chemotherapy and ...

The immune system is comprised of two separate active arms of immunity to provide robust protection against disease. The two separate systems of immunity include the innate and adaptive immune ...

Recent findings published in Scientific Reports highlight a promising target for ovarian cancer drug development, emphasizing the importance of Claudin-4 in tumor progression and resistance. The study ...

Cancer immunotherapy, which uses drugs that stimulate the body's immune cells to attack tumors, is a promising approach to treating many types of cancer. However, it doesn't work well for some tumors, ...

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for high-grade serous ovarian carcinoma (HGSOC). Patient selection for ADC therapy depends on tumour target expression, ...

New trials target hard-to-treat cancers with more personalized, less toxic therapies, including pediatric brain tumors, colorectal, ovarian, bladder cancers, and leukemia. FDA cleared Reyobiq for ...

Scientists uncover the ovarian cancer cause behind drug resistance and immune therapy failure - here's what the latest 2026 ...